2021 was an incredibly exciting year. Break Through Cancer was created, received its cornerstone funding, and established an incredible Board of Directors and an outstanding Scientific Advisory Board. We also began building a new research model: one based on Radical Collaboration, which is designed to find solutions to the most intractable challenges in cancer.

The Break Through Cancer model draws strength from unprecedented partnerships. At the core are interdisciplinary teams of researchers from five leading cancer research institutions: Dana-Farber Cancer Institute, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, The University of Texas MD Anderson Cancer Center, Memorial Sloan Kettering Cancer Center, and the Koch Institute for Integrative Cancer Research at Massachusetts Institute of Technology (MIT).

Our foundation was launched with a foundational $250 million pledge from William and Alice Goodwin, the Goodwin family, and the estate of William Hunter Goodwin, III. Their contributions, both financial and conceptual, are fundamental to our quest to find solutions to the deadliest cancers. And the memory of Hunter Goodwin—who helped shape our organization’s vision—is an enduring motivation for us.

We are proud to have undertaken this mission in collaboration with the Goodwins, our institutional partners, and the investigators driving our research projects.

Break Through Cancer is empowering scientists and clinicians to share discoveries and data in real-time; to display both trust and willingness to critique each other’s ideas; and be motivated by a sense of urgency, knowing that lives are at stake.
We realize there are no guarantees, yet we believe this effort to fight cancer, particularly with collaborative research, has a realistic probability of success. We want to help people have better lives. And we sincerely hope that by being public with our support, we will inspire others to support this incredible effort.

Bill and Alice Goodwin
Commonwealth Foundation for Cancer Research
In helping to remove the hurdles that cancer scientists and clinicians often face when trying to work across institutions, Break Through Cancer will be a powerful catalyst for new approaches to preventing, diagnosing, and treating cancer.

Lisa M. DeAngelis, MD
Physician-in-Chief & Chief Medical Officer, Memorial Sloan Kettering Cancer Center

David A. Scheinberg, MD, PhD
Memorial Sloan Kettering Cancer Center

John Sherman
Commonwealth Foundation for Cancer Research

Matt Vander Heiden, MD, PhD
MIT’s Koch Institute

--

Lisa M. DeAngelis, MD
Memorial Sloan Kettering Cancer Center

Giulio F. Draetta, MD, PhD
The University of Texas MD Anderson Cancer Center

Laurie Glimcher, MD
Dana-Farber Cancer Institute

Alice Goodwin
Commonwealth Foundation for Cancer Research

William H. Goodwin, Jr
Commonwealth Foundation for Cancer Research

William C. Hahn, MD, PhD
Dana-Farber Cancer Institute

Susan Hockfield, PhD
Massachusetts Institute of Technology

Tyler Jacks, PhD
President, Break Through Cancer, MIT’s Koch Institute for Integrative Cancer Research

Elizabeth M. Jaffee, MD, FAACR, FACP
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

David Jaffray, PhD
The University of Texas MD Anderson Cancer Center

William G. (Bill) Nelson, V, MD, PhD
Chairman of the Board, Break Through Cancer, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Camp Goodwin August  
Board Observer, Commonwealth Foundation for Cancer Research

Matthew Goodwin  
Board Observer, Commonwealth Foundation for Cancer Research

Wayne L. Hunter  
Board Observer, Commonwealth Foundation for Cancer Research

David Livingston, MD  
Special Advisor to the President, Break Through Cancer, Charles A. Dana Chair in Human Cancer Genetics, Dana-Farber Cancer Institute*

Craig B. Thompson, MD  
Board Observer, Break Through Cancer  
President and CEO, Memorial Sloan Kettering Cancer Center

*Sadly, David Livingston passed away in 2021. His leadership was instrumental in the creation of Break Through Cancer and we are forever grateful for his leadership.
Break Through Cancer’s Scientific Advisory Board (SAB) comprises distinguished cancer researchers and clinicians affiliated with seven leading academic medical centers and with a national research institute. SAB members are actively engaged in shaping initial research proposals into honed project plans that are both ambitious and feasible. They also help to evaluate the composition of the research team to ensure a highly effective range of expertise, perspective, and experience.

Cory Abate-Shen, PhD
Chair, Department of Molecular Pharmacology and Therapeutics, Vagelos College of Physicians and Surgeons, Columbia University

John D. Carpten, PhD
Chair, Translational Genomics; Director, Institute of Translational Genomics, Keck School of Medicine, University of Southern California

Timothy Cloughesy, MD
Director, Neuro-Oncology Program; Director, Henry Singleton Brain Cancer Research Program, University of California, Los Angeles

Benjamin Haibe-Kains, PhD
Senior Scientist, Princess Margaret Cancer Centre, University Health Network; Associate Professor, Department of Medical Biophysics, University of Toronto

Patricia LoRusso, DO
Associate Cancer Center Director, Experimental Therapeutics, Yale Cancer Center

Frank McCormick, PhD, FRS, DSc (Hon)
Professor, Helen Diller Family Comprehensive Cancer Center, Department of Cellular and Molecular Pharmacology, University of California, San Francisco

Miriam Merad, MD, PhD
Director, Precision Immunology Institute; Director, Mount Sinai Human Immune Monitoring Center, Icahn School of Medicine, Mount Sinai

Dinah Singer, PhD
Bethesda, MD

Louis M. Staudt, MD, PhD
Bethesda, MD

Alejandro Sweet-Cordero, MD
Director, Molecular Oncology Initiative, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco

E. John Wherry, PhD
Chair, Department of Systems Pharmacology and Translational Therapeutics; Director, Institute for Immunology, Perelman School of Medicine, University of Pennsylvania
## Statement of Financial Position

**Commonwealth Cancer Consortium, Inc. | Year Ended 12.31.2021**

### Assets

<table>
<thead>
<tr>
<th>Assets</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cash</td>
<td>$929,560</td>
</tr>
<tr>
<td>Pledges receivable due from related party, net of discount</td>
<td>$97,341,409</td>
</tr>
<tr>
<td>Prepaid expenses</td>
<td>$1,437</td>
</tr>
<tr>
<td><strong>Total assets</strong></td>
<td><strong>$98,272,406</strong></td>
</tr>
</tbody>
</table>

### Liabilities and Net Assets

<table>
<thead>
<tr>
<th>Liabilities</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Accounts payable and accrued expenses</td>
<td>$68,677</td>
</tr>
<tr>
<td><strong>Total liabilities</strong></td>
<td><strong>$68,677</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Net assets</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Net assets without donor restrictions</td>
<td>$18,840,542</td>
</tr>
<tr>
<td>Net assets with donor restrictions</td>
<td>$79,363,187</td>
</tr>
<tr>
<td><strong>Total net assets</strong></td>
<td><strong>$98,203,729</strong></td>
</tr>
</tbody>
</table>

| Total liabilities and net assets                 | **$98,272,406** |

"The Break Through Cancer model is empowering. We’re not limited by the knowledge and technical resources of any one lab or even any one institution—we are gathering exactly the experts and the technologies necessary to develop a practical method for preventing ovarian cancer."

---

**Rebecca Stone, MD**

Associate Professor & Division Chief of Gynecologic Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Statement of Cash Flow
Commonwealth Cancer Consortium, Inc.  | Year Ended 12.31.2021

### Cash flows from operating activities

<table>
<thead>
<tr>
<th>Description</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Increase in net assets</td>
<td>$98,203,729</td>
</tr>
<tr>
<td>Non-cash interest income</td>
<td>($157,618)</td>
</tr>
</tbody>
</table>

Adjustments to reconcile increase in net assets to net cash provided by operating activities

<table>
<thead>
<tr>
<th>Description</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Changes in operating assets and liabilities</td>
<td></td>
</tr>
<tr>
<td>Pledges receivable due from related party, net</td>
<td>($97,183,791)</td>
</tr>
<tr>
<td>Prepaid expenses</td>
<td>($1,437)</td>
</tr>
<tr>
<td>Accounts payable and accrued expenses</td>
<td>$68,677</td>
</tr>
</tbody>
</table>

Net cash provided by operating activities                                       | $929,560     |

Increase in cash and cash equivalents                                            | $929,560     |

Cash at beginning of year                                                        | –            |

**Cash at end of year**                                                          | **$929,560** |

Supplemental cash flow information

Non-cash discount on pledges receivable due from related party                  | $796,089     |
# Statement of Activities
Commonwealth Cancer Consortium, Inc.  | Year Ended 12.31.2021

<table>
<thead>
<tr>
<th></th>
<th>Net assets without donor restrictions</th>
<th>Net assets with donor restrictions</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Support and revenues</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contributions and grants</td>
<td>$353,546</td>
<td>$99,203,984</td>
<td>$99,557,530</td>
</tr>
<tr>
<td>Interest income</td>
<td>–</td>
<td>$157,618</td>
<td>$157,618</td>
</tr>
<tr>
<td>Net assets released from restrictions</td>
<td>$19,998,415</td>
<td>($19,998,415)</td>
<td>–</td>
</tr>
<tr>
<td><strong>Total support and revenue</strong></td>
<td><strong>$20,351,961</strong></td>
<td><strong>$79,363,187</strong></td>
<td><strong>$99,715,148</strong></td>
</tr>
<tr>
<td><strong>Support expenses</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Salaries and benefits</td>
<td>$1,282,866</td>
<td>–</td>
<td>$1,282,866</td>
</tr>
<tr>
<td>General and administrative</td>
<td>$228,553</td>
<td>–</td>
<td>$228,553</td>
</tr>
<tr>
<td><strong>Total support expenses</strong></td>
<td><strong>$1,511,419</strong></td>
<td>–</td>
<td><strong>$1,511,419</strong></td>
</tr>
<tr>
<td>Increase in net assets</td>
<td>$18,840,542</td>
<td>$79,363,187</td>
<td>$98,203,729</td>
</tr>
<tr>
<td>Net assets at beginning of year</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td><strong>Total support expenses</strong></td>
<td><strong>$18,840,542</strong></td>
<td><strong>$79,363,187</strong></td>
<td><strong>$98,203,729</strong></td>
</tr>
</tbody>
</table>